Bristol-Myers Squibb Other revenues — Total Revenues increased by 2.5% to $247.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 18.8%, from $304.00M to $247.00M. Over 3 years (FY 2021 to FY 2024), Other revenues — Total Revenues shows an upward trend with a 19.3% CAGR.
An increase may indicate successful monetization of intellectual property or growth in ancillary services, while a decrease suggests a narrowing focus on core therapeutic areas or the expiration of non-core revenue streams.
This metric represents the portion of total consolidated revenue derived from secondary business activities, ancillary s...
Most large-cap pharmaceutical peers report similar 'other' or 'miscellaneous' revenue categories, typically representing a small single-digit percentage of total sales, often driven by royalties or licensing agreements.
bmy_segment_other_revenues_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $153.50M | $153.50M | $153.50M | $152.00M | $203.00M | $232.00M | $159.00M | $145.00M | $130.00M | $183.00M | $162.00M | $172.00M | $160.00M | $304.00M | $407.00M | $227.00M | $241.00M | $247.00M |
| QoQ Change | — | +0.0% | +0.0% | -1.0% | +33.6% | +14.3% | -31.5% | -8.8% | -10.3% | +40.8% | -11.5% | +6.2% | -7.0% | +90.0% | +33.9% | -44.2% | +6.2% | +2.5% |
| YoY Change | — | — | — | — | +32.2% | +51.1% | +3.6% | -4.6% | -36.0% | -21.1% | +1.9% | +18.6% | +23.1% | +66.1% | +151.2% | +32.0% | +50.6% | -18.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.